Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model

Qelliny, Milad Reda; Aly, Usama Farghaly; Khaled, Khaled Aly

doi:10.1208/s12249-019-1453-5

Cited by 27 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the drug was released at pH higher than 7. 137,138 The pH at which the drug is released could be adjusted to lower values by mixing ES100 to other methacrylic acid co-polymers that dissolve at low pH. 139 Eudragit L100 is soluble at pH 6, while EL30-D55 was used to manipulate the drug release within the desired pH range of in the distal small intestine.…”

Section: Ph Changesmentioning

confidence: 99%

Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems

Hadji

Bouchemal

2022

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Section: Ph Changesmentioning

confidence: 99%

Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems

Hadji

Bouchemal

2022

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

“…Campos et al utilized CS with Eudragit in order to form swellable nanoparticles [12] while Bodas et al constructed CS nanoparticles cross-linked with dextran sulfate through a solvent evaporation method [13]. Eudragit was moreover utilized from Quellini et al which formulated pH-sensitive BUD loaded nanocapsules through a nanoprecipitation technique achieving controlled release of the drug [14]. Liu et al used hyaluronic acid in order to prepare microparticles containing BUD through spray dry, aiming in improving the poor solubility of the corticosteroid and ameliorate its pharmacological effect [15] whereas microparticles from poly(vinyl pyrrolidone) were constructed through a supercritical antisolvent method [16].…”

Section: Introductionmentioning

confidence: 99%

Effect of Poly(vinyl alcohol) on Nanoencapsulation of Budesonide in Chitosan Nanoparticles via Ionic Gelation and Its Improved Bioavailability

et al. 2020

View full text Add to dashboard Cite

Chitosan (CS) is a polymer extensively used in drug delivery formulations mainly due to its biocompatibility and low toxicity. In the present study, chitosan was used for nanoencapsulation of a budesonide (BUD) drug via the well-established ionic gelation technique and a slight modification of it, using also poly(vinyl alcohol) (PVA) as a surfactant. Scanning electron microscopy (SEM) micrographs revealed that spherical nanoparticles were successfully prepared with average sizes range between 363 and 543 nm, as were measured by dynamic light scattering (DLS), while zeta potential verified their positive charged surface. X-ray diffraction (XRD) patterns revealed that BUD was encapsulated in crystalline state in nanoparticles but with a lower degree of crystallinity than the neat drug, which was also proven by differential scanning calorimetry (DSC) and melting peak measurements. This could be attributed to interactions that take place between BUD and CS, which were revealed by FTIR and by an extended computational study. An in vitro release study of budesonide showed a slight enhancement in the BUD dissolution profile, compared to the neat drug. However, drug release was substantially increased by introducing PVA during the nanoencapsulation procedure, which is attributed to the higher amorphization of BUD on these nanoparticles. The release curves were analyzed using a diffusion model that allows estimation of BUD diffusivity in the nanoparticles.

show abstract

“…More recently, Qelliny and co-workers [ 136 ] developed pH-sensitive BUD-loaded Eudragit ® S100/Capryol 90 nanocapsules to solve the insufficient BUD amounts in diseased regions by preventing its release in non-inflamed GIT regions. The nanocapsules, optimized by a full 31 × 21 factorial design, presented a mean size of 171 nm, polydispersity around 0.127 and a negative zeta potential of about −37.6 mV.…”

Section: Benefits Of a Nanomedicine-based Therapy For Ibdmentioning

confidence: 99%

Drug Targeting of Inflammatory Bowel Diseases by Biomolecules

et al. 2021

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a group of disabling, destructive and incurable immune-mediated inflammatory diseases comprising Crohn’s disease (CD) and ulcerative colitis (UC), disorders that are highly prevalent worldwide and demand a large investment in healthcare. A persistent inflammatory state enables the dysfunction and destruction of healthy tissue, hindering the initiation and endurance of wound healing. Current treatments are ineffective at counteracting disease progression. Further, increased risk of serious side effects, other comorbidities and/or opportunistic infections highlight the need for effective treatment options. Gut microbiota, the key to preserving a healthy state, may, alternatively, increase a patient’s susceptibility to IBD onset and development given a relevant bacterial dysbiosis. Hence, the main goal of this review is to showcase the main conventional and emerging therapies for IBD, including microbiota-inspired untargeted and targeted approaches (such as phage therapy) to infection control. Special recognition is given to existing targeted strategies with biologics (via monoclonal antibodies, small molecules and nucleic acids) and stimuli-responsive (pH-, enzyme- and reactive oxygen species-triggered release), polymer-based nanomedicine that is specifically directed towards the regulation of inflammation overload (with some nanosystems additionally functionalized with carbohydrates or peptides directed towards M1-macrophages). The overall goal is to restore gut balance and decrease IBD’s societal impact.

show abstract

Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model

Cited by 27 publications

References 52 publications

Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems

Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems

Effect of Poly(vinyl alcohol) on Nanoencapsulation of Budesonide in Chitosan Nanoparticles via Ionic Gelation and Its Improved Bioavailability

Drug Targeting of Inflammatory Bowel Diseases by Biomolecules

Contact Info

Product

Resources

About